Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
Globe Newswire•28/10/2026•07:05 ET
0
Key Highlights
- ➤Lorundrostat 25 mg cut placebo-adjusted systolic blood pressure 7.5 mmHg at week four
- ➤Lorundrostat reduced UACR 25.6% placebo-adjusted at week four (p=0.0015)
- ➤Serum aldosterone fell 41.5% with lorundrostat versus increased 1.8% with placebo
- ➤24-hour UACR and urine protein-to-creatinine ratio fell 26.1% and 22.1%, respectively
- ➤Explore-CKD randomized 59 participants with uncontrolled hypertension, CKD and albuminuria
Expert Statements
Matthew R. Weir, Director of the Division of Nephrology at the University of Maryland Medical Center, Professor of Medicine at the University of Maryland School of Medicine, lead author and scientific consultant for Mineralys
“The Explore-CKD results demonstrate that lorundrostat may help CKD patients reduce otherwise uncontrolled high blood pressure and potentially improve their kidney function.”
Terry Ferguson, Chief Medical Officer of Mineralys Therapeutics
“There were consistent reductions in urinary protein loss, along with the expected reductions in serum aldosterone levels.”
- Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily added to an SGLT2 inhibitor achieved a statistically significant reduction in systolic blood pressure at four weeks -
- New hormonal and urinary protein data show a 41.5% reduction in serum aldosterone with additional significant reductions in albuminuria and proteinuria -
Get started
Create a free account to read the full story.